|
| Identification |
| Molecular Structure |
 |
CAS No. |
60142-96-3 |
| Molecular Formula |
C9H17NO2 |
| Molecular Weight |
171.34 |
| Name |
Gabapentin |
| Synonymous |
Gabapentin; Neurontin; 1-(aminomethyl)cyclohexaneacetic acid |
| Properties |
| Melting Point |
162-166℃(Satzinger); 165-167℃(Schmidt).
|
| Safety & Transportation Information |
| Harzard Symbols |
|
| Hs code |
|
| Supplier Specification |
| Appearance |
White or off-white crystalline powder
|
| Purity |
98%+
|
| Packages |
25kg/drum
|
| Productivity |
|
| Storage |
|
| Notes |
Gabapentin is only approved in the USA for the treatment of people with seizures. There are few systematic studies that establish the safety or efficacy of gabapentin as a treatment for people with mood disorders, anxiety or tardive dyskinesia. While such studies are in the progress, what is currently known about the use of gabapentin for the control of mood and anxiety disorders and tardive dyskinesia comes mostly from uncontrolled case reports. The few double-blind placebo-controlled studies that have been done to date have not demonstrated that gaba- pentin is an effective mood stbailizer.
Gabapentin is an anticonvulsant that is chemically unrelated to any other anticonvulsant or mood regulating medication. Gabapentin received final approval for marketing in the USA on 30 December 1993 and is labeled only for use as an anticonvulsant. It is also widely used to treat individuals suffering from many kinds of pain problems, tremors, restless legs syndrome, hot flashes associated with menopause, and various psychiatric disorders.
Gabapentin has had been successful in controlling rapid cycling and mixed bipolar states in a few people who have not received adequate relief from carbamazepine and/or valproate. It also appears that gabapentin has significantly more antianxiety and antiagitation potency than either carbamazepine or valproate. Gabapentin also may be useful as a treatoent for people with antipsychotic-induced tardive dyskinesia.
Gabapentin is an anticonvulsant drug that has a structure similar to that of -aminobytyric acid (GABA) but does not bind to GABA receptors. It increases nonsynaptic GABA release from the glia, and it is a substrate and a competitive inhibitor of the large neutral amino acid carrier system. Furthermore, gabapentin modulates (but does not directly block) sodium channels and increases human whole-blood serotonin concentrations. Finally, the drug may subtly modulate calcium channels by binding to the 2 subunit of voltage-dependent calcium channels, reducing monoamine release. Its favorable safety profile and lack of drug interactions make it an alternative for use in treating a variety of neurologic and psychiatric conditions.
Because gabapentin has a potential effect in the management of dementia-associated agitation, it has been suggested as an addition to haloperidol or donepezil treatment. Gabapentin also has been successfully used to treat behavioral dyscontrol in a 13-year-old boy with diagnoses of intermittent explosive disorder, attention deficit hyperactivity disorder, organic mood disorder, simple partial seizure disorder, and closed head injury. We report on an agitated woman with profound mental retardation due to Cornelia de Lange syndrome who was treated with gabapentin.
|
|
|
|